Two-dose recombinant shingles vaccine is effective even accounting for prior receipt of live shingles vaccine
A target trial emulation was conducted to assess the effectiveness of recombinant zoster vaccine (RZV) accounting for prior receipt of live zoster vaccine (ZVL) and immunocompetence. The results suggest individuals vaccinated with ZVL should be revaccinated with two doses of RZV.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.